Future of drugs-Heart Disease & Stroke_Ciraparantag

Let’s continue our series of Future of Drugs. We are now going to take you through the new drugs that are being developed and those that might actually get approved against the rising incidence of Heart Diseases and Stroke.
Ciraparantag has tremendous potential of competing with anticoagulants like edoxaban, rivaroxaban, dabigatran and apixaban.
Ciraparantag is to be administered IV. 

Drug Name
Ciraparantag
Structure
 
Drug Code
PER 977
Synonym
Aripazine
N,N'-(1,4-piperazinediyldi-3,1-propanediyl)bis[2-amino-5-[(aminoiminomethyl)amino]-, (2S,2'S)-pentanamide
Molecular Formula
C22H48N12O2
Innovator
Perosphere
Condition
Anticoagulant Reversal
Mechanism of Action
Blood coagulation factor modulators; Factor Xa inhibitors
Clinical Phase
II in USA (Fast Track Designation)
         

Comments

Popular posts from this blog

China-India joint summit discusses bilateral trade to improve pharma industry

PHYTOCON 2018 - Commercialization of medicinal plant products: Lab techniques to trade_14 April 2018